RESUMEN
Clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9CRISPR/Cas9gene editing system is derived from a prokaryotic adaptive immune system that confers resistance to invasion of exogenous DNA in bacteria and archaea. The CRISPR/Cas9 system is easier and more efficient in genome editing compared to conventional zinc finger nucleases (ZFN) and transcription- activator- like effector nucleases(TALEN)techniques. So far, this technique has been widely used in the field of cancer drug resistance research, such as breast cancer and leukemia drug resistance. Although the CRISPR/Cas9 system still has some problems such as off- target effects, it opens up a good prospect of application and extension. This review summarizes the progress in the application of CRISPR/Cas9 gene editing in cancer drug resistance.